Paclitaxel/mitoxantrone as first line chemotherapy for metastatic breast cancer

Although the association of paclitaxel (PTX) with doxorubicin (DOX) is highly promising in the treatment of metastatic breast cancer (MBC), its use may be Limited by the increasingly common use of DOX in adjuvant programs and by the high risk of cardiotoxicity associated to this regimen. For these reasons, we propose, as an alternative, the association of PTX with mitoxantrone (MZT), finding it to be an effective regimen, even in patients previously treated with anthracyclines, and well tolerated, with a low cardiotoxicity.